KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Twist Bioscience (TWST) Capital Expenditures (2017 - 2025)

Historic Capital Expenditures for Twist Bioscience (TWST) over the last 9 years, with Q4 2025 value amounting to $10.0 million.

  • Twist Bioscience's Capital Expenditures rose 33977.07% to $10.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $35.7 million, marking a year-over-year increase of 51168.21%. This contributed to the annual value of $28.0 million for FY2025, which is 45169.42% up from last year.
  • Latest data reveals that Twist Bioscience reported Capital Expenditures of $10.0 million as of Q4 2025, which was up 33977.07% from $12.4 million recorded in Q3 2025.
  • Twist Bioscience's 5-year Capital Expenditures high stood at $40.6 million for Q2 2022, and its period low was $603000.0 during Q1 2024.
  • For the 5-year period, Twist Bioscience's Capital Expenditures averaged around $9.8 million, with its median value being $8.2 million (2021).
  • In the last 5 years, Twist Bioscience's Capital Expenditures plummeted by 9333.92% in 2024 and then surged by 84974.09% in 2025.
  • Quarter analysis of 5 years shows Twist Bioscience's Capital Expenditures stood at $12.8 million in 2021, then fell by 7.5% to $11.8 million in 2022, then tumbled by 87.26% to $1.5 million in 2023, then skyrocketed by 50.6% to $2.3 million in 2024, then surged by 339.77% to $10.0 million in 2025.
  • Its Capital Expenditures was $10.0 million in Q4 2025, compared to $12.4 million in Q3 2025 and $9.2 million in Q2 2025.